Boule Diagnostics AB (CHIX:BOULS) Change In Receivables: kr28.6 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BOULS Boule Diagnostics AB CHIX:BOULS
47 GF Score
Price kr26.30
GF Value kr49.42
! 2 Warning Signs
View Full Analysis

What is Boule Diagnostics AB Change In Receivables?

Boule Diagnostics AB CHIX:BOULS 47 Change In Receivables is kr28.6 Mil as of Mar. 2026. GuruFocus rates CHIX:BOULS with a GF Score™ of 47/100 and a GF Value™ of kr49.42. The stock has 2 warning signs investors should review.

Boule Diagnostics AB's change in receivables for the quarter that ended in Mar. 2026 was kr10.5 Mil. It means Boule Diagnostics AB's Accounts Receivable declined by kr10.5 Mil from Dec. 2025 to Mar. 2026 .

Boule Diagnostics AB's change in receivables for the fiscal year that ended in Dec. 2025 was kr33.5 Mil. It means Boule Diagnostics AB's Accounts Receivable declined by kr33.5 Mil from Dec. 2024 to Dec. 2025 .

Boule Diagnostics AB's Accounts Receivable for the quarter that ended in Mar. 2026 was kr116.4 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Boule Diagnostics AB's Days Sales Outstanding for the three months ended in Mar. 2026 was 104.54.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Boule Diagnostics AB's liquidation value for the three months ended in Mar. 2026 was kr-159.6 Mil.

Boule Diagnostics AB  (CHIX:BOULs) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Boule Diagnostics AB's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=116.4/101.6*91
=104.54

2. In Ben Graham's calculation of liquidation value, Boule Diagnostics AB's accounts receivable are only considered to be worth 75% of book value:

Boule Diagnostics AB's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=18.5-297.3+0.75 * 116.4+0.5 * 63.9
=-159.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boule Diagnostics AB Change In Receivables Related Terms

Boule Diagnostics AB Change In Receivables Historical Data

* Premium members only.

The historical data trend for Boule Diagnostics AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boule Diagnostics AB Change In Receivables Chart

Boule Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.70 -15.15 -19.27 -8.99 33.48

Boule Diagnostics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.30 14.30 0.70 3.10 10.50
CHIX:BOULS
47GF Score
Boule Diagnostics AB CHIX:BOULS
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boule Diagnostics AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr28.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of kr28.6 Mil mean?
Boule Diagnostics AB (CHIX:BOULS) has a Change In Receivables of kr28.6 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Boule Diagnostics AB and its competitors.
Is Boule Diagnostics AB's Change In Receivables too high?
Boule Diagnostics AB's current Change In Receivables is kr28.6 Mil. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Change In Receivables compare to ABT and SYK?
Boule Diagnostics AB's Change In Receivables of kr28.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Boule Diagnostics AB and its competitors. Boule Diagnostics AB's current Change In Receivables is kr28.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Change In Receivables of kr28.6 Mil. The stock's GF Value™ is kr49.42, compared to a current price of kr26.30 — trading 46.8% below its estimated fair value. The current Change In Receivables is kr28.6 Mil. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Change In Receivables is kr28.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?

Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued. The current stock price of kr26.30 is trading 46.8% below its estimated GF Value™ of kr49.42.

Key valuation signals for CHIX:BOULS:

  • Change In Receivables: kr28.6 Mil
  • GF Value™: kr49.42 vs. price of kr26.30 (46.8% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boule Diagnostics AB Business Description

Other Exchanges BOUL:Sweden
Address Fagerstagatan 7, Spanga, SWE, SE-163 53
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score

Get the complete analysis for CHIX:BOULS

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr26.30
Price
kr49.42
GF Value